Next Article in Journal
A COL7A1 Variant in a Litter of Neonatal Basset Hounds with Dystrophic Epidermolysis Bullosa
Next Article in Special Issue
Distinct Effects of Inflammation on Cytochrome P450 Regulation and Drug Metabolism: Lessons from Experimental Models and a Potential Role for Pharmacogenetics
Previous Article in Journal
Development and Cell Cycle Activity of the Root Apical Meristem in the Fern Ceratopteris richardii
Previous Article in Special Issue
Using Personal Genomic Data within Primary Care: A Bioinformatics Approach to Pharmacogenomics
Review

Technologies for Pharmacogenomics: A Review

1
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2333ZA Leiden, The Netherlands
2
Leiden Network of Personalized Therapeutics, 2333ZA Leiden, The Netherlands
3
Department of Clinical Genetics, Leiden University Medical Center, 2333ZA Leiden, The Netherlands
*
Author to whom correspondence should be addressed.
Genes 2020, 11(12), 1456; https://doi.org/10.3390/genes11121456
Received: 13 November 2020 / Revised: 30 November 2020 / Accepted: 2 December 2020 / Published: 4 December 2020
The continuous development of new genotyping technologies requires awareness of their potential advantages and limitations concerning utility for pharmacogenomics (PGx). In this review, we provide an overview of technologies that can be applied in PGx research and clinical practice. Most commonly used are single nucleotide variant (SNV) panels which contain a pre-selected panel of genetic variants. SNV panels offer a short turnaround time and straightforward interpretation, making them suitable for clinical practice. However, they are limited in their ability to assess rare and structural variants. Next-generation sequencing (NGS) and long-read sequencing are promising technologies for the field of PGx research. Both NGS and long-read sequencing often provide more data and more options with regard to deciphering structural and rare variants compared to SNV panels—in particular, in regard to the number of variants that can be identified, as well as the option for haplotype phasing. Nonetheless, while useful for research, not all sequencing data can be applied to clinical practice yet. Ultimately, selecting the right technology is not a matter of fact but a matter of choosing the right technique for the right problem. View Full-Text
Keywords: pharmacogenomics; genotype; phenotype; next generation sequencing; long-read sequencing pharmacogenomics; genotype; phenotype; next generation sequencing; long-read sequencing
Show Figures

Figure 1

MDPI and ACS Style

van der Lee, M.; Kriek, M.; Guchelaar, H.-J.; Swen, J.J. Technologies for Pharmacogenomics: A Review. Genes 2020, 11, 1456. https://doi.org/10.3390/genes11121456

AMA Style

van der Lee M, Kriek M, Guchelaar H-J, Swen JJ. Technologies for Pharmacogenomics: A Review. Genes. 2020; 11(12):1456. https://doi.org/10.3390/genes11121456

Chicago/Turabian Style

van der Lee, Maaike, Marjolein Kriek, Henk-Jan Guchelaar, and Jesse J. Swen 2020. "Technologies for Pharmacogenomics: A Review" Genes 11, no. 12: 1456. https://doi.org/10.3390/genes11121456

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop